Tarsus Pharmaceuticals Q1 2025 10-Q Filing
Ticker: TARS · Form: 10-Q · Filed: May 1, 2025 · CIK: 1819790
| Field | Detail |
|---|---|
| Company | Tarsus Pharmaceuticals, Inc. (TARS) |
| Form Type | 10-Q |
| Filed Date | May 1, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, quarterly-report, biotech, financials
TL;DR
**Tarsus Pharma Q1 2025 10-Q filed. Focus on product & licensing revenue. Check financials for growth.**
AI Summary
Tarsus Pharmaceuticals, Inc. filed its quarterly report for the period ending March 31, 2025. The company's primary business is in Biological Products, with a focus on products and licensing/collaboration revenue streams. Financial data for the first quarter of 2025 and comparative periods in 2024 are presented.
Why It Matters
This filing provides investors with an update on Tarsus Pharmaceuticals' financial performance and business activities for the first quarter of 2025, crucial for assessing the company's current health and future prospects.
Risk Assessment
Risk Level: medium — As a company in the biological products sector, Tarsus Pharmaceuticals faces inherent risks related to product development, regulatory approvals, and market competition.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the end of the fiscal quarter for which financial information is reported.)
- 2025-01-01 — Reporting Period Start Date (Indicates the beginning of the fiscal quarter for which financial information is reported.)
- 2024-03-31 — Prior Year Quarter End Date (Provides a comparative point for the current quarter's financial performance.)
- 2024-12-31 — Prior Fiscal Year End Date (Provides context for year-end financial position and comparison.)
Key Players & Entities
- Tarsus Pharmaceuticals, Inc. (company) — Filer of the 10-Q report
- 20250331 (date) — End of the reporting period
- 20250501 (date) — Filing date of the report
- 15440 LAGUNA CANYON ROAD (address) — Company's business and mailing address
- IRVINE, CA (address) — Company's business and mailing city and state
- 92618 (zip_code) — Company's business and mailing zip code
- (949) 409-9820 (phone_number) — Company's business phone number
FAQ
What is the primary business of Tarsus Pharmaceuticals, Inc. according to this filing?
Tarsus Pharmaceuticals, Inc. is primarily involved in Biological Products (NO DIAGNOSTIC SUBSTANCES), as indicated by its Standard Industrial Classification code [2836].
What is the reporting period for this 10-Q filing?
The Conformed Period of Report is 20250331, meaning the filing covers the period ending March 31, 2025.
When was this 10-Q filing submitted to the SEC?
The filing was submitted on 20250501.
What are the main revenue segments mentioned for Tarsus Pharmaceuticals?
The filing mentions 'Product' revenue and 'LicenseAndCollaboration' revenue as key segments.
What is the company's principal business address?
The company's business address is 15440 LAGUNA CANYON ROAD, IRVINE, CA 92618.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 1, 2025 regarding Tarsus Pharmaceuticals, Inc. (TARS).